Ubs Asset Management Americas Inc Cullinan Oncology, Inc. Transaction History
Ubs Asset Management Americas Inc
- $446 Billion
- Q3 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 47,163 shares of CGEM stock, worth $403,243. This represents 0.0% of its overall portfolio holdings.
Number of Shares
47,163
Previous 106,580
55.75%
Holding current value
$403,243
Previous $802,000
65.21%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding CGEM
# of Institutions
149Shares Held
65.1MCall Options Held
10.7KPut Options Held
14.4K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$65.4 Million8.21% of portfolio
-
Lynx1 Capital Management LP San Juan, PR5.77MShares$49.3 Million6.64% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$49.2 Million1.84% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$30.4 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$29.2 Million15.23% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $390M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...